Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of its ...
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...
Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corbus Pharmaceuticals (CRBP – Research ...
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...